Steve Neavling
ticklethewire.com
The DEA has obstructed research into the medical benefits of marijuana in an attempt to keep the drug from being reclassified, according to a new report, AlJazeera reports.
“The DEA impedes research by abusing its discretionary powers over the scheduling process, making it difficult to obtain marijuana for research purposes.
We recommend taking away the DEA’s power over drug scheduling and access to drugs for research,” Ethan Nadelmann, executive director of the Drug Policy Alliance (DPA), said Wednesday during a teleconference.
The report, “The DEA: Four Decades of Impending and Rejecting Science,” urges the DEA to end its objections to marijuana research that could be used to help patients in need.
“The DEA has created a Catch-22 — saying that the FDA didn’t approve marijuana therefore it’s bogus, while at the same time obstructing FDA research necessary for approval,” Jag Davies, publications manager for DPA, said.
Despite impeding research, the DEA continues to insist that there’s not enough evidence to support rescheduling marijuana to Schedule 2, a move that would allow for medical use.
OTHER STORIES OF INTEREST
- FBI Returns Database of Taxpayer Information It Got From IRS
- Former FBI Informant Pleads Guilty to Federal Drug Charge
- New York City Strippers Accused of Drugging Wealthy Men
- Homeland Security Chief in Tough Position Over Surge in Illegal Immigration
- FBI Director Says Face-Tracking Technology Not for Civilians
